SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

Sepúlveda‐Sánchez, Juan Manuel; Langa, J. Muñoz; Arráez, Miguel Ángel Escribano; Fuster, José Luís; Laín, Aurelio Hernández; Reynés, Gaspar; González, V. Rodríguez; Vicente, E.; Denis, María; Gallego, Óscar

doi:10.1007/s12094-017-1790-3

Cited by 34 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Usually, astrocytomas are confined in the white matter, meanwhile the oligodendrogliomas are cortical-based tumor, but this difference is attenuated in the later stages ( Figure 2). Cystic components are not infrequent and low contrast enhancement could be observed in 20% of cases without malignant transformation [19]. Advanced MRI techniques such as diffusion-weighted imaging (DWI) and MRI spectroscopy will complete the anatomical information, while the functional MRI and diffusion tensor imaging (DTI) will offer important data for surgical planning.…”

Section: Diffuse Astrocytoma Idh-mutant (Da Idh-mut)mentioning

confidence: 99%

“…Concerning adjuvant radiotherapy, the recommendation is in favor of lower doses (45-50.4 Gy) which are equivalent in terms of results with the high doses (59.4-64.8 Gy) but with reduced toxicity. Relative to chemotherapeutic regimen, actual data suggest that the PCV (procarbazine, CCNU, and vincristine) formula is superior to temozolomide regimen in terms of overall survival for the treatment of DA IDH-mut, mostly in cases with codeletion of 1p/19q genes [19].…”

Section: Adjuvant Therapymentioning

confidence: 99%

See 1 more Smart Citation

Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management

Florian¹,

Şuşman²

2019

Glioma - Contemporary Diagnostic and Therapeutic Approaches

View full text Add to dashboard Cite

For the first time, the WHO classification of brain tumors has introduced molecular parameters in the diagnosis of brain tumors. Together with embryonal tumors, the diffuse gliomas have suffered significant changes in diagnosis, prognosis, and response to treatment. A new concept of "integrated diagnosis" comes to combine the classical diagnosis with the molecular one. While it is still impossible to disregard the histopathological component, according to the new rule ("molecular beats histology") makes molecular parameters dominant in the final diagnosis. Currently, the diffuse gliomas (oligodendroglial or astrocytic) are nosologically closer than the astrocytomas with a diffuse growth pattern, and the astrocytomas with a more circumscribed growth pattern defined by the presence of the IDH mutation. The family tree was redefined by the presence of the IDH mutation and of the 1p/19q codeletion. The implementation of this new concept in clinical practice will improve patient management, as well as the design of clinical trials and experimental studies. This must also be seen as a model for diagnosis setting in the new molecular era.

show abstract

Section: Diffuse Astrocytoma Idh-mutant (Da Idh-mut)mentioning

confidence: 99%

Section: Adjuvant Therapymentioning

confidence: 99%

Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management

Florian¹,

Şuşman²

2019

Glioma - Contemporary Diagnostic and Therapeutic Approaches

View full text Add to dashboard Cite

show abstract

“…In clinical practice, multi-modal magnetic resonance imaging (MRI) is the primary method of screening and diagnosis of gliomas. While gliomas are commonly stratified into Low grade and High grade due to different histology and imaging aspects, prognosis and treatment strategy, radiotherapy is one of the mainstays of treatment (Stupp et al, 2014;Sepúlveda-Sánchez et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Deep Learning-Based Concurrent Brain Registration and Tumor Segmentation

Estienne

Lerousseau

Vakalopoulou

et al. 2020

Front. Comput. Neurosci.

View full text Add to dashboard Cite

“…Almost invariable transformation of LGA into aggressive anaplastic astrocytoma (AA) and to secondary glioblastoma (GBM) is ultimately fatal. The timescale for transformation is unpredictable and the mechanisms causing them to become aggressive are poorly characterized …”

Section: Introductionmentioning

confidence: 99%

Integrated systems‐genetic analyses reveal a network target for delaying glioma progression

Laaniste

Srivastava

Stylianou

et al. 2019

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective To identify a convergent, multitarget proliferation characteristic for astrocytoma transformation that could be targeted for therapy discovery. Methods Using an integrated functional genomics approach, we prioritized networks associated with astrocytoma progression using the following criteria: differential co‐expression between grade II and grade III IDH1‐mutated and 1p/19q euploid astrocytomas, preferential enrichment for genetic risk to cancer, association with patient survival and sample‐level genomic features. Drugs targeting the identified multitarget network characteristic for astrocytoma transformation were computationally predicted using drug transcriptional perturbation data and validated using primary human astrocytoma cells. Results A single network, M2, consisting of 177 genes, was associated with glioma progression on the basis of the above criteria. Functionally, M2 encoded physically interacting proteins regulating cell cycle processes and analysis of genome‐wide gene‐regulatory interactions using mutual information and DNA–protein interactions revealed the known regulators of cell cycle processes FoxM1, B‐Myb, and E2F2 as key regulators of M2. These results suggest functional disruption of M2 via gene mutation or altered expression as a convergent pathway regulating astrocytoma transformation. By considering M2 as a multitarget drug target regulating astrocytoma transformation, we identified several drugs that are predicted to restore M2 expression in anaplastic astrocytoma toward its low‐grade profile and of these, we validated the known antiproliferative drug resveratrol as down‐regulating multiple nodes of M2 including at nanomolar concentrations achievable in human cerebrospinal fluid by oral dosing. Interpretation Our results identify M2 as a multitarget network characteristic for astrocytoma progression and encourage M2‐based drug screening to identify new compounds for preventing glioma transformation.

show abstract

SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

Cited by 34 publications

References 29 publications

Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management

Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management

Deep Learning-Based Concurrent Brain Registration and Tumor Segmentation

Integrated systems‐genetic analyses reveal a network target for delaying glioma progression

Contact Info

Product

Resources

About